For example, identification of a somatic pathogenic variant in the BRCA1 or BRCA2 genes following tumor profiling may lead to personalized treatment with a PARP inhibitor [29], but it may also be indicative of Hereditary Breast and Ovarian Cancer syndrome if present in the germline [30, 31]. This evidence concerns the gene BRCA2 and hereditary breast ovarian cancer syndrome.